Dr. Kenneth M. Heym
Claim this profileCook Children's Medical Center
Expert in Leukemia
Studies Acute Myelogenous Leukemia
17 reported clinical trials
58 drugs studied
About Kenneth M. Heym
Education:
- MD (Doctor of Medicine), specific institution and graduation year not provided.
Experience:
- Serves as the Medical Director of the Vascular Anomalies Clinic at Cook Children's Hematology and Oncology Center.
- Has been overseeing the Cook Children's Vascular Anomalies Clinic since its inception.
- An active member of the American Society of Pediatric Hematology / Oncology Vascular Anomalies Special Interest Group (ASPHO VA-SIG) for nearly a decade.
- Engaged in local and national research projects focused on vascular anomalies.
- Authored or co-authored several peer-reviewed manuscripts on vascular anomalies, including a notable publication in Pediatr Blood Cancer (2022).
Area of expertise
1Leukemia
Global LeaderBCR-ABL1 fusion positive
ABL-class fusion positive
MRD positive
2Acute Myelogenous Leukemia
FLT3 positive
t(9;11) positive
inv(16) positive
Affiliated Hospitals
Clinical Trials Kenneth M. Heym is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
More about Kenneth M. Heym
Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Kenneth M. Heym has experience with
- Cytarabine
- Methotrexate
- Dexamethasone
- Cyclophosphamide
- Mercaptopurine
- Thioguanine
Breakdown of trials Kenneth M. Heym has run
Leukemia
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kenneth M. Heym specialize in?
Kenneth M. Heym focuses on Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Leukemia has involved BCR-ABL1 fusion positive patients, or patients who are ABL-class fusion positive.
Is Kenneth M. Heym currently recruiting for clinical trials?
Yes, Kenneth M. Heym is currently recruiting for 6 clinical trials in Fort Worth Texas. If you're interested in participating, you should apply.
Are there any treatments that Kenneth M. Heym has studied deeply?
Yes, Kenneth M. Heym has studied treatments such as Cytarabine, Methotrexate, Dexamethasone.
What is the best way to schedule an appointment with Kenneth M. Heym?
Apply for one of the trials that Kenneth M. Heym is conducting.
What is the office address of Kenneth M. Heym?
The office of Kenneth M. Heym is located at: Cook Children's Medical Center, Fort Worth, Texas 76104 United States. This is the address for their practice at the Cook Children's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.